Skip to main content
Premium Trial:

Request an Annual Quote

Regulus Preclinical Data Shows Liver Cancer Biomarker Potential of microRNAs


Regulus Therapeutics this week announced the presentation of preclinical data showing that circulating microRNAs may be effective biomarkers for determining tumor growth and systemic response disease in liver cancer.

The findings were released at this year's American Association for Cancer Research annual meeting.

Among Regulus' oncology efforts are programs focusing on miR-21 and miR-221, both of which have been linked to liver cancer. As part of its research in the area, the company looked at whether circulating miRNAs could act as disease biomarkers in a mouse model of the disease.

According to a poster presented at AACR, Regulus investigators found that deregulation of liver miRNA profiles increases with tumor size and that miRNAs in serum "reflect both changes in tumor tissues and systemic response to tumor burden."

Notably, most of the changes in both liver and serum are reversed upon inhibition of the driving oncogene — in the case of the animal models, HRAS.

"Thus, circulating microRNAs are promising candidates for tumor detection, as well as monitoring disease progression and treatment response," the scientists concluded in their poster.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.